Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2011, Vol. 31 Issue (9): 140-145    DOI:
    
Research on The Competitiveness of Regional Biomedical Industry——Taking Shijiazhuang as Example
ZHAO Bing1, ZHANG Dong-sheng2, ZHAO Yong-zheng3
1. Shijiazhuang University, Shijiazhuang 050035 ,China;
2. Hebei University of Technology, Tianjin 300401, China;
3. CSPC Pharmaceutical Group Limited,Shijiazhuang 050051, China
Download: HTML   PDF(626KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

According to the characteristics of biomedical industry and Porter's Diamond model, forming a six factors diamond model.Taking Shijiazhuang as example, analysis of six elements which affecting the industrial competitiveness,such as production factors, demand, related and supporting industries elements, structure and competition elements of corporate strategy, government, innovation. And illustrates the path of enhancing its competitiveness, such as select the appropriate cluster development model based on comparative advantage and local conditions, actively promote the combination of government, industry, academia, research and medical, through various means to improve innovation, actively undertake the outsourcing services of biomedical industry, strengthen the agency and information to support the construction,improve the social and cultural support for the biomedical industry, etc., in order to ensure the Shijiazhuang sustainable development of biomedical industry.



Key wordsDiamond model      Biomedical industry      Competitiveness      Shijiazhuang      Strategy     
Received: 13 May 2011      Published: 25 September 2011
ZTFLH:  Q789  
Cite this article:

ZHAO Bing, ZHANG Dong-sheng, ZHAO Yong-zheng. Research on The Competitiveness of Regional Biomedical Industry——Taking Shijiazhuang as Example. China Biotechnology, 2011, 31(9): 140-145.

URL:

https://manu60.magtech.com.cn/biotech/     OR     https://manu60.magtech.com.cn/biotech/Y2011/V31/I9/140


[1] 刘敏,褚淑贞.基于钻石模型的江苏省医药产业竞争力研究.上海医药,2011,32(1):27-31. Liu M,Zhu S Z. Shanghai Medicine&Pharmaceutical Journal, 2011,32(1):27-31.

[2] 赵策.燕赵大地崛起"生物谷". 中国高新技术产业导报.2008-12-17 .http://paper.chinahightech.com.cn/html/2008-12/15/content_8127.htm. Zhao C. China High-tech Industry Herald, 2008-12-17 .http://paper.chinahightech.com.cn/html/2008-12/15/content_8127.htm.

[3] 雷汉发,刘俊德.石家庄大力发展规模工业见成效.经济日报, 2008-06-18 .http://paper.ce.cn/jjrb/html/2008-06/18/content_19067.htm. Lei H F,Liu J D. Economic Daily, 2008-06-18 .http://paper.ce.cn/jjrb/html/2008-06/18/content_19067.htm.

[4] 常幸.重点培育和优先发展生物医药产业.河北企业,2004,(5-6):22-24. Chang X, Hebei Enterprise,2004(5-6):22-24.

[5] 焦莉莉.医药创新路在何方.石家庄日报, 2011-04-11 .http://sjzrb.sjzdaily.com.cn/html/2011-04/11/content_322596.htm. Jiao L L. Shijiazhuang Daily, 2011-04-11 .http://sjzrb.sjzdaily.com.cn/html/2011-04/11/content_322596.htm.

[6] 张晋之,徐怀伏.中国医药产业集群发展的竞争策略初探.现代经济,2007(10):151-153. Zhang J Z, Xu H F, Modern Economics, 2007(10):151-153.

[7] 王冬梅.湖北省生物医药产业集群培育策略研究.科技进步与对策,2009,26(12):47-49. Wang D M, Science&Technology Progress and Policy, 2009,26(12):47-49.

[1] SHI Peng-cheng, JI Xiao-jun. Advances in Expression of Human Epidermal Growth Factor in Yeast[J]. China Biotechnology, 2021, 41(1): 72-79.
[2] YIN Zheng-qing,BAI Jing-yu,LIN Xiao-feng. Competitiveness Analysis and Enlightenment of Biomedical Industry in USA[J]. China Biotechnology, 2020, 40(9): 87-94.
[3] YANG Na,WU Qun,XU Yan. Fermentation Optimization for the Production of Surfactin by Bacillus amyloliquefaciens[J]. China Biotechnology, 2020, 40(7): 51-58.
[4] HUANG Peng-fei,CHEN Yun,LU Jiao,MAO Kai-yun,YUAN Yin-chi. Development Situation and Suggestions of Biomedicine Patent-intensive Industry, Based on the Case Study of Shanghai[J]. China Biotechnology, 2020, 40(12): 108-116.
[5] KONG Jian-tao,ZHUANG Ying-ping,GUO Mei-jin. Enhancement of Anti-CD20 Monoclonal Antibody Expression by CHO based on DOE and Amino Acid Supplemental Strategy[J]. China Biotechnology, 2020, 40(12): 41-48.
[6] Zheng-san ZUO,Xiao-man SUN,Lu-jing REN,He HUANG. Improvement of Lipid Accumulation in Microalgae by Novel Cultivation Strategies[J]. China Biotechnology, 2018, 38(7): 102-109.
[7] LIN You-hong, CHENG Xia-ying, YAN Yi-wen, LIANG Zong-suo, YANG Zong-qi. Expression and Optimization Strategy of Recombinant Proteins in Chlamydomonas Chloroplast[J]. China Biotechnology, 2017, 37(10): 118-125.
[8] ZHENG Ying, DENG Yong, CHEN Fang, CHEN Yun-wei, DING Chen-jun. Analyzing the Strategy of Bio-based Science and Technology[J]. China Biotechnology, 2016, 36(4): 116-122.
[9] WU Qing, LIU Hui-yan, FANG Hai-tian, HE Jian-guo, HE Xiao-guang, YU Li-nan, WANG Meng-jiao. Metabolic Control Fermentation Mechanism and Breeding Strategies of Cytidine Excessive Biosynthesis in Bacillus amyloliquefaciens[J]. China Biotechnology, 2015, 35(9): 122-127.
[10] PU Run, LI Ping-ping, SU Yue, ZHU Min, HUA Yu-tao. Development Statuses and Future Suggestions of Biomedical Parks in China[J]. China Biotechnology, 2015, 35(3): 104-106.
[11] NIE Guang-jun, YUE Wen-jin, XUE Zheng-lian, YANG Chao-yin, ZHAO Shi-guang, YAO Zhen-yun, SUN Wu-yue, NIE Zhi-jie, YE Yu-chao. Bio-imprinting: A Straightforward Technique for Enzyme Modification[J]. China Biotechnology, 2014, 34(9): 122-128.
[12] WANG Jing-yao, WANG Tian-nv, LU Lei, ZHANG Shuai, ZHAO Min. Research Advances in Secretary Production of Recombinant Protein Using Escherichia coli Type I Secretion System and Strategies for Enhancement of Secretion of Type I Pathway[J]. China Biotechnology, 2014, 34(06): 98-104.
[13] SONG Min, LIU Na, REN Xin-xin, LU Yao. Analysis of Intellectual Property Protection Strategy of Transnational Biotechnology Corporation——Taking MON531 of Cotton Event for Example[J]. China Biotechnology, 2014, 34(06): 110-116.
[14] LIU Bo-ning. The Technology Progress of Antibody-producing Cell Line Development[J]. China Biotechnology, 2013, 33(6): 111-116.
[15] CHEN Chen, TAI Chao, LI Shuang. Search for Optimum Substitutive Neutralizing Agent and pH Control Strategy in Fumaric Acid Fermentation by Rhizopus oryzae[J]. China Biotechnology, 2013, 33(4): 85-91.